Spiegelmer AON-D21 showed synergistic anti-tumor effects when used in conjunction with an anti-PD-1 mAb, owing to lower MDSC populations and increased CD8+ T cells with decreased expression of exhaustion markers. This evidence concerns the gene CD8A and neoplasm.